1. Applying Data to Practice

3. Program Goals

4. Clinical Recommendations for Basal Insulin Therapy in Type 2 Diabetes

6. Metformin Plus Liraglutide Followed by Add-on of Detemir

7. Insulin Glargine 300 U/mL (U-300) Similar Efficacy and Lower Nocturnal Hypoglycemia Rates vs U-100

8. Insulin Degludec PK/PD Profile Stable, Ultra-long Acting Basal Activity

9. Insulin Degludec “Flexible” Treatment Regimen

10. Investigational Basal Insulin Peglispro (BIL)*

11. Physiology of Insulin BIL* Hypothesis

12. IDegLira* Is Superior to Glargine in HbA1c Reduction

13. Where Do Coformulation GLP-1 Agonist/Basal Insulin Fit?

14. Insulin Glargine U-300 Dosing

15. Titrating Ultra-Long Acting Basal Insulins

17. Reasons for Delaying Initiation of Basal Insulin

18. Clinical Caveats With Next-Generation Basal Insulin Analogs

19. Closing Comments

20. Abbreviations

21. References

22. References (cont)

23. References (cont)

24. References (cont)

25. References (cont)

26. References (cont)

27. References (cont)